JP2012524120A5 - - Google Patents

Download PDF

Info

Publication number
JP2012524120A5
JP2012524120A5 JP2012507283A JP2012507283A JP2012524120A5 JP 2012524120 A5 JP2012524120 A5 JP 2012524120A5 JP 2012507283 A JP2012507283 A JP 2012507283A JP 2012507283 A JP2012507283 A JP 2012507283A JP 2012524120 A5 JP2012524120 A5 JP 2012524120A5
Authority
JP
Japan
Prior art keywords
derivative
derivatives
biologically active
peptides
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012507283A
Other languages
English (en)
Other versions
JP2012524120A (ja
JP6101077B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/031559 external-priority patent/WO2010123798A2/en
Publication of JP2012524120A publication Critical patent/JP2012524120A/ja
Publication of JP2012524120A5 publication Critical patent/JP2012524120A5/ja
Application granted granted Critical
Publication of JP6101077B2 publication Critical patent/JP6101077B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (1)

  1. 生物学的に活性な組成物であって、
    (a)以下の生物学的に活性な成分:
    (i)核酸又はその誘導体、
    (ii)ヌクレオシド、ヌクレオチド、又はヌクレオシド若しくはヌクレオチドの誘導体、
    (iii)ペプチド、タンパク質、又はペプチド若しくはタンパク質の誘導体、
    (iv)リポ多糖又はその誘導体、
    (v)ペプチドグリカン又はその誘導体、
    (vi)炭水化物又はその誘導体、
    (vii)脂質又はその誘導体、
    (viii)リポペプチド又はその誘導体、
    (ix)金属イオン、
    (x)チオール、
    (xi)抗生物質又はその誘導体、
    (xii)ビタミン又はその誘導体、
    (xiii)バイオフラボノイド又はその誘導体、
    (xiv)抗酸化物質又はその誘導体、
    (xv)免疫応答修飾因子、
    (xvi)抗体、
    (xvii)生物学的に活性な非金属、
    (vxiii)ヒスタミン又は抗ヒスタミン剤、及び
    (xix)キナーゼ阻害剤
    のうち少なくとも1種と
    (b)前記組成物を食細胞に送達し、その結果、生物学的に活性な成分が、食細胞によって取り込まれ、その生物活性に影響を及ぼすのに有効な少なくとも1種の生体高分子の担体と
    を含む上記組成物。
JP2012507283A 2009-04-20 2010-04-19 生体分子を細胞へトランスフェクトするための組成物 Active JP6101077B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17094509P 2009-04-20 2009-04-20
US61/170,945 2009-04-20
PCT/US2010/031559 WO2010123798A2 (en) 2009-04-20 2010-04-19 Compositions for transfection of biomolecules into cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015171776A Division JP6295235B2 (ja) 2009-04-20 2015-09-01 生体分子を細胞へトランスフェクトするための組成物

Publications (3)

Publication Number Publication Date
JP2012524120A JP2012524120A (ja) 2012-10-11
JP2012524120A5 true JP2012524120A5 (ja) 2013-06-06
JP6101077B2 JP6101077B2 (ja) 2017-03-22

Family

ID=43011700

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012507283A Active JP6101077B2 (ja) 2009-04-20 2010-04-19 生体分子を細胞へトランスフェクトするための組成物
JP2015171776A Expired - Fee Related JP6295235B2 (ja) 2009-04-20 2015-09-01 生体分子を細胞へトランスフェクトするための組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015171776A Expired - Fee Related JP6295235B2 (ja) 2009-04-20 2015-09-01 生体分子を細胞へトランスフェクトするための組成物

Country Status (7)

Country Link
US (1) US11738084B2 (ja)
EP (1) EP2421952B1 (ja)
JP (2) JP6101077B2 (ja)
KR (1) KR101742332B1 (ja)
AU (1) AU2010239463B2 (ja)
HU (1) HUE028642T2 (ja)
WO (1) WO2010123798A2 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6101077B2 (ja) * 2009-04-20 2017-03-22 ガレンバイオ、インコーポレイテッド 生体分子を細胞へトランスフェクトするための組成物
JP6208767B2 (ja) * 2012-10-23 2017-10-04 エコール スペリュール デ フィジーク エ シミ アンドゥストリエル デ ラ ヴィル デ パリ 複数回逐次的に形成し、切断することができる可逆的共有結合を含む粒子
CN103849650B (zh) * 2013-10-14 2018-08-03 王深明 功能化纳米姜黄素的基因导入材料及制备方法
NZ745881A (en) 2016-02-04 2023-04-28 Auransa Inc Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
CN108330102B (zh) * 2018-03-14 2020-02-14 江南大学 一株泰妙菌素单克隆抗体杂交瘤细胞株及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4954515A (ja) 1972-10-03 1974-05-27
US5602244A (en) 1988-05-26 1997-02-11 Competitive Technologies, Inc. Polynucleotide phosphorodithioate compounds
JP2524406B2 (ja) * 1988-07-05 1996-08-14 田辺製薬株式会社 パイロジェン定量方法
KR100191223B1 (ko) 1989-07-28 1999-06-15 둘락 노먼 씨. 인터루킨-4의 정제방법 및 이를 함유하는 약제학적 조성물
US6001982A (en) 1993-07-29 1999-12-14 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
US5962674A (en) 1995-06-01 1999-10-05 Hybridon, Inc. Synthesis of oligonucleotides containing alkylphosphonate internucleoside linkages
JPH10510433A (ja) 1995-06-06 1998-10-13 アイシス・ファーマシューティカルス・インコーポレーテッド 高いキラル純度のホスホロチオエート結合を有するオリゴヌクレオチド
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US5734041A (en) 1995-10-20 1998-03-31 Mcgill University Preparation of chiral phosphorothioate oligomers
US6194469B1 (en) 1998-12-11 2001-02-27 Board Of Trustees Operating Michigan State Univeristy Method for inhibiting cyclooxygenase and inflammation using cherry bioflavonoids
IL144597A0 (en) * 1999-02-03 2002-05-23 Powderject Res Ltd Hydrogel particle formulations
US7195780B2 (en) * 2002-10-21 2007-03-27 University Of Florida Nanoparticle delivery system
WO2002002131A2 (en) 2000-06-29 2002-01-10 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
JP2005519990A (ja) * 2001-10-12 2005-07-07 ユニバーシティ オブ アイオワ リサーチ ファウンデーション イミダゾキノリン化合物を用いて免疫応答を増強するための方法および産物
DE60304989T2 (de) 2003-02-18 2007-03-29 Clinique La Prairie Research S.A. Zusammensetzungen enthaltend fötales Hämoglobin und bakterielles Endotoxin und fakultativ zusätzliche fötale Leberkomponenten
US7785769B2 (en) * 2003-07-25 2010-08-31 The United States of America as reprsented by the Secretary of the Navy Immobilization of oligonucleotides and proteins in sugar-containing hydrogels
ZA200707249B (en) * 2005-01-28 2010-08-25 Galen Bio Inc Immunologically active compositions
US20070020620A1 (en) * 2005-07-14 2007-01-25 Finn M G Compositions and methods for coupling a plurality of compounds to a scaffold
US20070281036A1 (en) * 2005-12-19 2007-12-06 University Of Vermont And State Agricultural College System and method of delivering a desired material to a cell
US8288124B2 (en) * 2008-11-20 2012-10-16 Abbott Laboratories Cloning, expression and purification of recombinant porcine intrinsic factor for use in diagnostic assay
JP6101077B2 (ja) * 2009-04-20 2017-03-22 ガレンバイオ、インコーポレイテッド 生体分子を細胞へトランスフェクトするための組成物
ES2397909B1 (es) * 2011-05-05 2014-06-06 Universidad De Zaragoza Procedimiento de obtención de materiales multifuncionalizados

Similar Documents

Publication Publication Date Title
JP2021074025A5 (ja)
JP2012524120A5 (ja)
De Clercq Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections
AR124140A2 (es) Formulaciones de anticuerpos
Govorkova et al. Combination chemotherapy for influenza
Bandara et al. Pseudomonas aeruginosa lipopolysaccharide inhibits C andida albicans hyphae formation and alters gene expression during biofilm development
MX2011003843A (es) Incorporacion de adyuvante en inmunonanoterapeuticos.
BR112014001907A2 (pt) produção de dha e outros lc-pufas em plantas
EA200970273A1 (ru) Применение 2-6-(3-аминопиперидин-1-ил)-3-метил-2,4-диоксо-3,4-дигидро-2н-пиримидин-1-илметил-4-фторбензонитрила
PE20230684A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro como inhibidores de la arn polimerasa
BRPI0516323A (pt) construtos de rna
BR112015000710A8 (pt) Oligonucleotídeos para fazer uma alteração na sequência de um presente alvo de molécula de rna em uma célula viva
Müller et al. Morphogenetic (mucin expression) as well as potential anti-corona viral activity of the marine secondary metabolite polyphosphate on A549 cells
JP2013514797A5 (ja)
JP2013508315A5 (ja)
JP2015523072A5 (ja)
JP2016510747A5 (ja)
Paoletti et al. Multifaceted roles of purinergic receptors in viral infection
WO2010123798A3 (en) Compositions for transfection of biomolecules into cells
JP2010053122A5 (ja)
JP2010536929A5 (ja)
CL2014002896A1 (es) Una formulacion farmaceutica en la forma de una tableta recubierta que consiste de a) un nucleo obtenido a partir de una co-mezcla de manitol, croscarmelosa de sodio y al menos un compuestos activo, y b) un recubrimiento el cual se aplica en la forma de una solucion acuosa o que contiene agua y alcohol, y donde la tableta se desintegra rapidamente en presencia de humedad; y su proceso de preparacion.
AU2016204400A1 (en) Method of inducing an immune response
PE20140962A1 (es) Una formulacion farmaceutica solida
WO2010132047A8 (en) Guanosine/gmp gels and uses thereof